Extent of Atypical Hyperplasia Does Not Contribute to Breast Cancer Risk

Extent of atypical ductal hyperplasia or atypical lobular hyperplasia does not significantly contribute to breast cancer risk.
Extent of atypical ductal hyperplasia or atypical lobular hyperplasia does not significantly contribute to breast cancer risk.

The extent of atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH) does not significantly contribute to breast cancer risk, a new study published online ahead of print in the journal Cancer has shown.1

Although previous research has demonstrated an association between atypical hyperplasia on a benign breast biopsy specimen and breast cancer risk, the relation between the type or extent of ADH or ALH and the magnitude of the breast cancer risk is not clear.

For the nested case-control study, researchers identified 488 cases of women with breast cancer and prior benign breast biopsy findings matched with 1907 controls who had prior benign breast biopsy findings but no breast cancer.

Results showed no significant association between the extent of atypia and breast cancer risk among women with ADH or ALH. In other words, women with ADH with 1 or 2 foci of atypical hyperplasia had a similar risk for developing breast cancer compared with those with 3 or more foci. Women with ALH with 3 more foci had a higher risk than those with less than 3, but the difference was not statistically significant.

“The lack of a significant dose-response relation between the extent and type of atypia and breast cancer risk suggests that it would be premature to use the extent of atypia to influence management decisions for women with ADH or ALH,” the authors note.

REFERENCE

1. Collins LC, Aroner SA, Connolly JL, et al. Breast cancer risk by extent and type of atypical hyperplasia: an update from the Nurses' Health Studies [published online ahead of print November 13, 2015]. Cancer. doi:10.1002/cncr.29775.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs